Evidence map›Paper›PMID 40734477›Full record

ArticleImmunity, inflammation and disease2025

RETRACTION: Calycosin Inhibits Hepatocyte Apoptosis in Acute Liver Failure by Suppressing the TLR4/NF-κB Pathway: An In Vitro Study.

Abstract readRetraction Notice
In one paragraph

Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

retractionL. Chang, A. Zhang, W. Liu, P. Cao, L. Dong, and X. Gao, "Calycosin Inhibits Hepatocyte Apoptosis in Acute Liver Failure by Suppressing the TLR4/NF-κB Pathway: An In Vitro Study," Immunity, Inflammation and Disease 11, no. 7 (2023): e935, https://doi.org/10.1002/iid3.935. The above article, published online on July 12, 2023, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Marc Veldhoen; and John Wiley & Sons, Ltd. The retraction was agreed upon following an investigation into concerns raised by a third party regarding unexpected similarity between the flow cytometry data in Figure 2C of this article and data published earlier in a separate article by a different group of authors. Inconsistencies were also observed in the western blot presented in Figure 5A of this article. The authors provided supporting data for the flow cytometry plots in Figures 2C and 7C; however, the data did not align with the figures presented in the published article. Additionally, they did not address or provide any data in response to concerns regarding the western blot. Given these issues and the lack of adequate supporting data, the editors find the article's results and conclusions to be unreliable. The authors were informed of the decision to retract but did not respond to requests for comment.

Identifiers

PMID40734477
PMCPMC12308069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.